ACRS Aclaris Therapeutics Inc

Price (delayed)

$18.16

Market cap

$1.11B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.46

Enterprise value

$1.01B

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The ...

Highlights
ACRS's equity has soared by 108% QoQ
Aclaris Therapeutics's quick ratio has surged by 75% QoQ
ACRS's gross profit has soared by 66% YoY but it is down by 5% from the previous quarter
Aclaris Therapeutics's EPS has increased by 40% YoY but it has decreased by 4.3% QoQ

Key stats

What are the main financial stats of ACRS
Market
Shares outstanding
61.22M
Market cap
$1.11B
Enterprise value
$1.01B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.05
Price to sales (P/S)
147.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
152.28
Earnings
Revenue
$6.63M
EBIT
-$70.93M
EBITDA
-$70.25M
Free cash flow
-$45.82M
Per share
EPS
-$1.46
Free cash flow per share
-$0.85
Book value per share
$4.49
Revenue per share
$0.12
TBVPS
$5.21
Balance sheet
Total assets
$288.05M
Total liabilities
$54.23M
Debt
$11.38M
Equity
$233.82M
Working capital
$226.35M
Liquidity
Debt to equity
0.05
Current ratio
16.17
Quick ratio
15.59
Net debt/EBITDA
1.45
Margins
EBITDA margin
-1,059.6%
Gross margin
25.5%
Net margin
-1,067.1%
Operating margin
-743.9%
Efficiency
Return on assets
-47.8%
Return on equity
-66.7%
Return on invested capital
-79.8%
Return on capital employed
-26%
Return on sales
-1,069.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACRS stock price

How has the Aclaris Therapeutics stock price performed over time
Intraday
4.01%
1 week
2.95%
1 month
35.62%
1 year
614.96%
YTD
180.68%
QTD
3.42%

Financial performance

How have Aclaris Therapeutics's revenue and profit performed over time
Revenue
$6.63M
Gross profit
$1.69M
Operating income
-$49.32M
Net income
-$70.75M
Gross margin
25.5%
Net margin
-1,067.1%
ACRS's gross profit has soared by 66% YoY but it is down by 5% from the previous quarter
ACRS's net margin is up by 42% YoY but it is down by 14% from the previous quarter
Aclaris Therapeutics's gross margin has increased by 39% YoY but it has decreased by 2.3% QoQ
Aclaris Therapeutics's operating margin has increased by 37% YoY but it has decreased by 7% from the previous quarter

Growth

What is Aclaris Therapeutics's growth rate over time

Valuation

What is Aclaris Therapeutics stock price valuation
P/E
N/A
P/B
4.05
P/S
147.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
152.28
Aclaris Therapeutics's EPS has increased by 40% YoY but it has decreased by 4.3% QoQ
ACRS's equity has soared by 108% QoQ
ACRS's P/B is 37% below its last 4 quarters average of 6.4 but 19% above its 5-year quarterly average of 3.4
ACRS's P/S is 52% above its last 4 quarters average of 97.2
The company's revenue rose by 20% YoY but it fell by 3.2% QoQ

Efficiency

How efficient is Aclaris Therapeutics business performance
Aclaris Therapeutics's return on invested capital has surged by 58% YoY and by 29% QoQ
The company's return on equity has surged by 57% YoY and by 38% QoQ
The ROA has increased by 48% YoY and by 28% from the previous quarter
Aclaris Therapeutics's return on sales has increased by 41% YoY but it has decreased by 14% QoQ

Dividends

What is ACRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACRS.

Financial health

How did Aclaris Therapeutics financials performed over time
Aclaris Therapeutics's total assets has soared by 78% from the previous quarter
Aclaris Therapeutics's quick ratio has surged by 75% QoQ
ACRS's debt is 95% less than its equity
ACRS's equity has soared by 108% QoQ
The debt to equity has dropped by 78% year-on-year and by 50% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.